阿托伐他汀調(diào)脂治療對冠心病合并代謝綜合征患者血脂水平及心腦血管事件發(fā)生率的影響分析

張貴平

【摘要】 目的：探討分析阿托伐他汀調(diào)脂治療對冠心病合并代謝綜合征患者血脂水平及心腦血管事件發(fā)生率的影響。方法：從2015年8月-2016年8月本院收治的冠心病合并代謝綜合征患者中采取數(shù)字隨機法抽取100例進行觀察（觀察組），并抽取同期收治的單純冠心病血脂異常患者100例（對照組），所有患者均使用阿托伐他汀進行調(diào)脂，比較兩組治療后血脂水平變化及心腦血管發(fā)生率。結(jié)果：治療前兩組TC、LDL-C、ApoA1及ApoB-100水平比較，差異均無統(tǒng)計學意義（P>0.05），觀察組TG、HDL-C水平比對照組均顯著更高（P<0.05）；治療后對照組TG、TC、HDL-C及LDL-C水平較治療前均顯著降低（P<0.05），觀察組TC、LDL-C水平較治療前均明顯降低（P<0.05），TG、HDL-C較治療前無明顯變化（P>0.05）；在心腦血管事件發(fā)生率上比較，觀察組顯著高于對照組（P<0.05）。結(jié)論：冠心病合并代謝綜合征患者使用阿托伐他汀治療后不能達到理想的血脂水平，仍存在高TG、低HDL-C的血脂特點，且使用阿托伐他汀治療后并不能控制該類患者心腦血管事件的發(fā)生。

【關(guān)鍵詞】 阿托伐他汀； 冠心病； 代謝綜合征； 血脂； 心腦血管事件

【Abstract】 Objective：To probe into and analyze the influence of Atorvastatin lipid-lowering therapy for level of blood lipid and the incidence of cardio cerebrovascular events in patients with coronary heart disease complicated with metabolic syndrome.Method：100 cases of patients with coronary heart disease complicated with metabolic syndrome and who accepted treatments in our hospital from August 2015 to August 2016 were selected by digital random method as the observation group，while other 100 cases of coronary heart disease patients with dyslipidemia were selected as the control group.All patients were treated with Atorvastatin lipid-lowering therapy.Then，the changes of blood lipid levels and the incidence rate of cardiovascular and cerebrovascular diseases of two groups after the treatment were compared.Result：There were no significant differences in the levels of TC，LDL-C，ApoA1 and ApoB-100 between two groups before treatment（P>0.05），while the levels of TG and HDL-C of the observation group were significantly higher than those of the control group（P<0.05）.The levels of TG，TC，HDL-C and LDL-C of the control group after the treatment were significantly lower than those before treatment（P<0.05）.The levels of TC and LDL-C of the observation group were significantly lower than those before treatment（P<0.05）.There were no significant differences in TG and HDL-C（P>0.05）.The incidence of cardio cerebrovascular events were compared，the observation group was significantly higher than that of the control group（P<0.05）.Conclusion：The patients with coronary heart disease complicated with metabolic syndrome do not achieve the ideal level of blood lipid after atorvastatin treatment，there are still high TG and low HDL-C lipid characteristics，and the use of Atorvastatin do not control the occurrence of cardiovascular events in this patient.

【Key words】 Atorvastatin； Coronary heart disease； Metabolic syndrome； Blood lipids； Cardiovascular eventsendprint

First-authors address：Traditional Chinese Medicine Hospital of Danjiangkou City，Danjiangkou 442700，China

doi：10.3969/j.issn.1674-4985.2017.29.008

冠心病是臨床十分常見的一種心臟病，其發(fā)病率高，危害性大，常會引起各種心腦血管事件發(fā)生，他汀類調(diào)脂藥物是治療冠心病的常用藥物，該藥可使患者發(fā)生心血管事件的幾率降低，使患者預后得到有效改善[1-3]。不過臨床大量研究顯示，即使使用他汀類調(diào)脂藥物治療冠心病，冠心病患者發(fā)生心腦血管事件的風險仍然很高，且風險與血脂的異常密切相關(guān)，主要體現(xiàn)在冠心病合并代謝綜合征患者中[4-6]。本研究探討分析阿托伐他汀調(diào)脂治療對冠心病合并代謝綜合征患者血脂水平及心腦血管事件發(fā)生率的影響，以作進一步證實，現(xiàn)報道如下。

1 資料與方法

1.1 一般資料 從2015年8月-2016年8月本院收治的冠心病合并代謝綜合征患者中采取數(shù)字隨機法抽取100例作為觀察組，并抽取同期收治的單純冠心病血脂異常患者100例作為對照組。此次……